LONDON, July 11, 2023 (GLOBE NEWSWIRE) — PMcardio, a leading force in
AI-powered diagnostics for cardiovascular diseases, announces expansion
into 15 additional European markets with the launch of its newest
version.
After a successful initial launch in the United Kingdom, with over 25
000 registered users, PMcardio is now making its state-of-the-art
application accessible to healthcare professionals in Germany, France,
Belgium, The Netherlands, Austria, Switzerland, Portugal, Italy,
Luxembourg, Lichtenstein, Cyprus, Poland, Ireland, Croatia and Malta.
PMcardio has further fine-tuned its clinical assistant, offering new
language support for French, German, Italian, and Portuguese, ensuring a
seamless experience for healthcare professionals across these diverse
regions.
For medical professionals in primary and emergency care who do not
specialise in cardiology, such as general practitioners, nurses and
paramedics – ECG interpretation can be challenging, leading to
inaccuracies and potential misdiagnoses.
_”The __increasing prevalence__ of diseases such as __atrial
fibrillation__, a condition that one in three people will experience in
their lifetime, highlights a __pressing need for more reliable solutions
for early detection and effective treatment__,”_ states Dr. Robert
Herman, Chief Medical Officer of Powerful Medical, the deep-tech firm
behind PMcardio. _”This condition significantly escalates the risk of
stroke, making prompt and accurate diagnosis critical. PMcardio is
poised to enhance AF diagnosis and management at the first point of
contact.”_
Easily accessible in the form of a smartphone application, PMcardio
enables any healthcare professional to diagnose and treat 38
cardiovascular diseases with the precision of a cardiologist.
Not only does the CE-certified Class IIb medical device empower medical
personnel to interpret ECGs and identify cardiac conditions with
precision and speed – it also generates guideline-adherent treatment
recommendations personalised for each patient.
_“With PMcardio we’re aiming to save 1 million lives within the next
5 years.__ This European expansion is a significant leap in PMcardio’s
mission to combat __cardiovascular diseases, the world’s leading cause
of death__. Its integration can significantly improve clinical
decision-making, quality of care and outcomes of patients suffering from
heart disease across Europe,”_ concludes Martin Herman, CEO of
Powerful Medical.
About PMcardio
PMcardio is the market leader in AI-powered diagnostics, addressing the
world’s leading cause of death – cardiovascular diseases. The
certified Class IIb medical device empowers healthcare professionals to
diagnose 38 cardiovascular diseases with the precision of a
cardiologist. Backed by world’s leading cardiologists and clinical
institutions, PMcardio digitises and interprets any 12-lead ECG in under
5 seconds to provide accurate diagnoses and guideline-adherent treatment
recommendations tailored to each patient.
